Drug Profile
AR 18F112
Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Class
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 31 Dec 2006 Discontinued - Preclinical for Obesity in Japan (unspecified route)
- 24 Apr 2002 Preclinical trials in Obesity in Japan (unspecified)